ClinicalTrials.gg
CompletedNCT02974010STABIL-BUpdated May 25, 2021Results posted

Sequential Therapy for the Treatment of Severe Bipolar Depression.

A Phase 2 interventional study of NRX-101 Oral Capsule and Lurasidone Oral Capsule in Bipolar Depression, Suicidal Ideas and Suicidal Ideation, sponsored by NeuroRx, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-05-25.

Sponsored by NeuroRx, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Enrollment
546th of 704
22 · median 58
Started
2018
with 25 others
Phase 2
92 of 837
9 open now
Registered
584th of 837
by date

Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 546th largest by enrollment of the 704 interventional ones that give a count, is one of 26 that started in 2018, is one of 92 in phase 2, and was the 584th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 837 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or 5) or Behavior (ASIB) in following initial stabilization. Patients with Severe Bipolar Depression and ASIB will be recruited in both inpatient and outpatient settings and, following informed consent, will be given an intravenous infusion of ketamine 0.5mg/kg over 40 minutes. Those who exhibit a satisfactory clinical response to ketamine will be randomly allocated to NRX-101 or to lurasidone alone (the comparator group). This study is conducted as a feasibility study for a pivotal phase 2b/3 clinical trial and the primary outcomes for this phase 2 study were blood levels of NRX-101, in order to confirm pharmaco-kinetics with remission from depression, as measured by BISS-derived MADRS and relapse as secondary outcomes.

Read the detailed description

NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of D-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation or Behavior (ASIB) in adults with Bipolar Depression following initial stabilization with ketamine. In recent years, intravenous and intranasal ketamine have demonstrated rapid and potent effects in achieving remission from both depression and suicidal ideation in both bipolar depression and major depressive disorder. However ketamine is will understood to induce hallucination and other dissociative side effects, to be addictive and have high abuse potential, and to have potential neurotoxic effects. Moreover, ketamine can only be administered in a monitored hospital or clinic setting. NRX-101 was developed with the objective of seeking a safe, non-hallucinogenic, non-addictive, oral medication that might maintain the effects of ketamine in patients with severe depression and acute suicidal ideation and which might be considered as initial therapy for patients with depression and non-acute suicidal ideation. The D-cycloserine component of NRX-101 is believed to act by inhibiting the brain's NMDA receptor and raising levels of glutamate/glutamine (Glx) in the anterior cingulate cortex. Increased Glx, as measured by magnetic resonance spectroscopy, has been associated with clinical improvement following electroconvulsive therapy (ECT) and following administration of IV ketamine.

The proposed oral combination product is intended to be administered as part of a sequential therapy consisting of the following 2 components:

  1. an initial, one-time intravenous (iv) infusion of ketamine (0.5 mg/kg administered over 40 min), followed one day later by
  2. twice daily oral capsules of NRX 101 (DCS + lurasidone), dosing of which is initiated 1 day after ketamine administration, titrated over 5 days to a maintenance dose and continued for up to 6 weeks. Each NRX-101 oral capsule contains DCS (237.5 or 175.0 mg) and lurasidone (8.25, 16.5, or 33.0 mg). It is anticipated that subjects entering the study will be receiving concurrent disorder-directed treatment with other approved medications. This treatment regime will be maintained upon entry into the study. However, any use of lurasidone, quetiapine, or olanzapine will be stopped at study entry, so as to avoid either duplication with study drug (groups 1 and 2) or undermining of the control group.

The clinical efficacy goal is to provide extended relief from symptoms associated with Severed Bipolar Depression and ASIB in adults with Bipolar Disorder, after initial stabilization with iv ketamine in a clinic, emergency department, or inpatient setting.

The proposed NRX-101 product takes advantage of a unique synergistic confluence of combining two active pharmaceutical ingredients (DCS and lurasidone) that respectively inhibit the NMDA and the D2/5-HT2A receptors in the brain. NMDA receptor antagonists, most notably ketamine, have been shown in many studies to rapidly reduce depressive and suicidal ideation. However, numerous studies have demonstrated the potential of NMDA antagonists to cause hallucination and other dissociative side effects. Similarly, D2/5HT2A receptor antagonists, such as lurasidone have demonstrated antidepressant effects in bipolar depression, but have demonstrated a propensity to cause akathisia in some patients. The goals of combining these drugs into a single course of treatment is to maximize the beneficial effects of the specific subcomponents while overcoming potential treatment-limiting side effects associated with those subcomponents.

Beneficial effects of the proposed dosage regimen include 1) well-documented pharmacodynamic effects of ketamine in treating both persistent depressive symptoms and suicidal ideation in bipolar disorder (McCloud, 2015; Naughton, 2014; Newport, 2015; Price, 2014), 2) well-documented pharmacodynamic effects of oral DCS against persistent symptoms of depression (Heresco-Levy, 2013) and 3) the FDA-approved efficacy of lurasidone in treatment-resistant depression (Sunovion Pharmaceuticals, 2013). Due to the synergistic effects, the proposed NRX-101 combination capsule is also expected to avoid or minimize the significant undesired adverse effects associated with the usage of these drugs as single agents (eg, negative consequences of repeated use of ketamine (JHP Pharmaceuticals, 2012), potential psychotomimetic effects of long-term treatment with DCS alone (Kantrowitz, 2010) and potential akathisia and susceptibility for increased suicidality associated with lurasidone alone (Sunovion Pharmaceuticals, 2013).

The risk of ASIB is higher in bipolar depression than other psychiatric disorder and the majority of currently available antidepressants are contraindicated for patients with bipolar depression. NeuroRx believes that the proposed NRX-101 treatment regimen (ketamine administration followed by NRX-101) will demonstrate superiority over ketamine followed by lurasidone in maintaining remission from depression and in delaying the time to documented relapse from depression and suicidality in bipolar disorder, providing a new treatment option for patients with Severe Bipolar Depression and ASIB.

There is currently no FDA-approved product for the treatment of ASIB. NeuroRx proposes that NRX-101 will fulfill an urgent medical need for safe and effective treatment for ASIB.

Patients with Severe Bipolar Depression and ASIB will be recruited in inpatient settings and, following informed consent, will be given an intravenous infusion of either ketamine 0.5mg/kg over 40 minutes or normal saline (placebo). Those who exhibit a satisfactory clinical response to ketamine will be randomly allocated to NRX-101 or to lurasidone along (the comparator group). The primary outcome variable for this phase 2 study will be blood level (pharmacokinetic) exposure of NRX-101 and its D-cycloserine component with remission from depression, as measured on the MADRS scale and relapse as secondary endpoints. Relapse is defined as return of either depression or suicidality OR the need to alter therapy, which might include re-hospitalization, additional antidepressant medication, or electroconvulsive therapy (ECT).

03

Conditions studied

  • Bipolar Depression
  • Suicidal Ideas
  • Suicidal Ideation
  • Suicide, Attempted

Keywords

  • d-cycloserine
  • lurasidone
  • ketamine
  • randomized controlled trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  1. Male or female, 18 to 65 years of age, inclusive, at screening.
  2. Able to read, understand, and provide written, dated prior to screening. Participants will be deemed likely to comply with study protocol and communicate with study personnel about AEs and other information.
  3. Diagnosed with Bipolar Disorder (BD) according to the criteria defined in the . The diagnosis of BD will be made by a site psychiatrist and supported by the MINI 7.0.2. The diagnosis will be confirmed by remote, independent raters, via teleconference between the screen visit and the baseline visit.
  4. Suicidal ideation or behavior of sufficient severity to meet the requirements for a score of 4, or 5 on the C-SSRS (suicide attempt, interrupted attempt, aborted attempt, preparatory actions toward imminent suicidal behaviors, active method, intent +/- plan).
  5. A score equal to or greater than 20 on the MADRS items of the BISS.
  6. In good general health, in the opinion of the investigator, as ascertained by medical history, physical examination (PE) (including measurement of seated vital signs), clinical laboratory evaluations, and (ECG).
  7. If female, a status of non- or use of an acceptable form of per the following specific criteria:

    a. Non-childbearing potential (e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized [status post hysterectomy, bilateral tubal ligation], or is with her last menses at least one year prior to screening); or

    • Childbearing potential, and meets the following criteria:

      • Childbearing potential, including women using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent.
      • Negative urinary pregnancy test at screening, confirmed by a negative urinary pregnancy test at randomization prior to receiving study treatment.
      • Willing and able to continuously use one of the following methods of birth control during the course of the study, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline.
  8. between 18-35 kg/m2.
  9. Concurrent psychotherapy will be allowed if the type (e.g., supportive, cognitive behavioral, insight-oriented) and frequency (e.g., weekly or monthly) of the therapy has been stable for at least three months prior to screening and if the type and frequency of the therapy is expected to remain stable during the course of the subject's participation in the study.
  10. Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, benzodiazepines or trazodone) will be allowed if the therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable during the course of the subject's participation in the study. Subjects can also continue treatment with benzodiazepines used for sleep or anxiety if therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable during the course of the subject's participation in the study.

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Female of childbearing potential who is not willing to use one of the specified forms of birth control during the study.
  2. Female that is pregnant or breastfeeding.
  3. Female with a positive pregnancy test at screening or baseline.
  4. Current diagnosis of a substance use disorder (abuse or dependence, as defined by DSM-5, with the exception of nicotine dependence), at screening or within 6 months prior to screening.
  5. Current Axis I disorder, diagnosed at screening with the use of the MINI 7.0.2, that is the primary focus of treatment and BD the secondary focus of treatment for the past 6 months or more.
  6. History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms.
  7. History of anorexia nervosa, bulimia nervosa, or eating disorder not otherwise specified, within 5 years of screening.
  8. Any Axis I or Axis II Disorder, which at screening is clinically predominant to their BD or has been predominant to their BD at any time within 6 months prior to screening.
  9. Has dementia, delirium, amnestic, or any other cognitive disorder.
  10. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study clinician.
  11. Participation in any clinical trial with an drug or device within the past month or concurrent to study participation.
  12. Current episode of:

    • Hypertension, Stage 1 as defined by a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at screening on two of three measurements at least 15 minutes apart.
    • Hypertension, Stage 1 as defined by a systolic blood pressure ≥155 mmHg or diastolic blood pressure ≥99 mmHg at the Baseline Visit (Visit 1) within 1.5 hours prior to ketamine infusion on two of three measurements at least 15 minutes apart.
    • Recent myocardial infarction (within one year) or a history of myocardial infarction.
    • Syncopal event within the past year.
    • Congestive heart failure (CHF) Criteria >Stage 2
    • Angina pectoris.
    • Heart rate \<50 or >105 beats per minute at screening or randomization (Baseline Visit).
    • (Fridericia-corrected) ≥450 msec at screening or randomization (Baseline Visit).
  13. Current history of hypertension, or on antihypertensives for the purpose of lowering blood pressure, with either an increase in antihypertensive dose or increase in the number of antihypertensive drugs used to treat hypertension over the last 2 months.
  14. Chronic lung disease excluding asthma.
  15. Lifetime history of surgical procedures involving the brain or meninges, encephalitis, meningitis, degenerative central nervous system (CNS) disorder (e.g., Alzheimer's or Parkinson's Disease), epilepsy, mental retardation, or any other disease/procedure/accident/intervention which, according to the screening clinician, is deemed associated with significant injury to or malfunction of the CNS, or history of significant head trauma within the past 2 years.
  16. Presents with any of the following lab abnormalities:

    • Subjects with diabetes mellitus fulfilling any of the following criteria:

      • Unstable diabetes mellitus defined as glycosylated () >8.5% at screening.
      • Admitted to hospital for treatment of diabetes mellitus or diabetes mellitus-related illness in the past 12 weeks.
      • Not under physician care for diabetes mellitus.
      • Has not been on the same dose of oral hypoglycemic drug(s) and/or diet for the 4 weeks prior to screening. For thiazolidinediones (glitazones) this period should not be less than 8 weeks.
    • Any other clinically significant abnormal laboratory result (determined as such by the investigator and medical monitor) at the time of the screening.
  17. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
  18. Positive screening urine test for drugs of abuse at screening: cocaine, amphetamines, barbiturates, opiates.
  19. Subjects with exclusionary laboratory values, or requiring treatment with exclusionary concomitant medications as defined in the study manual
  20. Subjects on exclusionary concomitant psychotropic medications.
  21. Subjects with a lifetime history of illicit PCP/ketamine drug use or previous failed use of ketamine for depression.
  22. Liver Function Tests higher than 2.5 times as defined in the study manual.
  23. Known allergies to Lurasidone or Latuda, Cycloserine or Seromycin, Mannitol, Croscarmellose Sodium, Magnesium Stearate, Silicon Dioxide, and/or HPMC (hydroxypropylmethylcellulose)

    -

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    NRX-101

    NRX-101 is a fixed dose combination of d-cycloserine and lurasidone

    Drug: NRX-101 Oral Capsule · Drug: Ketamine Intravenous Infusion · Drug: Saline Solution Intravenous Infusion

  • Active comparator
    Lurasidone

    Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101

    Drug: Lurasidone Oral Capsule · Drug: Ketamine Intravenous Infusion · Drug: Saline Solution Intravenous Infusion

Interventions

  • Prospective Randomized Factorial Design Study as per arm/group descriptions

    Also known as: D-cycloserine + Lurasidone Fixed Dose Combination

  • Prospective Randomized Factorial Design Study as per arm/group descriptions

    Also known as: Lurasidone Fixed Dose Combination

  • Randomized administration of Ketamine or Placebo in a 3 to 1 ratio

  • DrugSaline Solution Intravenous Infusion

    Randomized administration of Ketamine or Placebo in a 3 to 1 ratio

06

What researchers measure

Primary outcomes

  1. BDM Score (BISS-derived MADRS) Change From Baseline at Day 42

    The study will measure the difference on BISS-derived MADRS score between NRX-101 and lurasidone (comparator) groups. The Bipolar Inventory of Symptom Scale (BISS) is a validated 42-item clinician-rated scale (21 items each for the depression and mania subscales) in which each item is rated on a 0-4 severity scale where higher values indicate worse severity. BISS-derived MADRS (BDM): MADRS is a 10-item clinician-rated scale, with each item rated on a 0-6 severity scale, where a higher number indicates worse severity. Responses to each question are equally weighted and summed. The BDM has a minimum score of 0 and a maximum of 40, where higher scores indicate a worse severity, therefore decreases in average BDM are considered a better outcome. Data are presented as mean change from baseline (end of stage 1, Day 1) using LOCF

    Time frame: Day 42

07

Results

Posted May 25, 2021

Participant flow

Participant flow — Overall Study
MilestoneKetamine Followed by NRX-101Ketamine Followed by LurasidoneSaline Followed by NRX-101Saline Followed by Lurasidone
Started12541
Completed6221
Not completed6320
Withdrew: Lost to follow-up3100
Withdrew: Withdrawal by subject2100
Withdrew: Adverse event0100
Withdrew: Completed day 42 but did not return for day 701010
Withdrew: Lack of efficacy0010

Outcome measures

PrimaryBDM Score (BISS-derived MADRS) Change From Baseline at Day 42

The study will measure the difference on BISS-derived MADRS score between NRX-101 and lurasidone (comparator) groups. The Bipolar Inventory of Symptom Scale (BISS) is a validated 42-item clinician-rated scale (21 items each for the depression and mania subscales) in which each item is rated on a 0-4 severity scale where higher values indicate worse severity. BISS-derived MADRS (BDM): MADRS is a 10-item clinician-rated scale, with each item rated on a 0-6 severity scale, where a higher number indicates worse severity. Responses to each question are equally weighted and summed. The BDM has a minimum score of 0 and a maximum of 40, where higher scores indicate a worse severity, therefore decreases in average BDM are considered a better outcome. Data are presented as mean change from baseline (end of stage 1, Day 1) using LOCF

Time frame:
Day 42
Reported as:
Least squares mean · score on a scale
BDM Score (BISS-derived MADRS) Change From Baseline at Day 42
score on a scaleKetamine Followed by NRX-101Ketamine Followed by LurasidoneSaline Followed by NRX-101Saline Followed by Lurasidone
Day 23.3 ± 1.952.4 ± 2.95-1.06 ± 3.810 ± 0
Day 72.0 ± 1.914.8 ± 2.95-0.5 ± 3.740 ± 0
Day 142.2 ± 1.9111.4 ± 2.950.31 ± 4.00 ± 0
Day 214.5 ± 1.9110.0 ± 2.951.0 ± 5.720 ± 0
Day 283.5 ± 1.9111.2 ± 2.951.69 ± 7.340 ± 0
Day 352.8 ± 1.9110.8 ± 2.951.75 ± 8.430 ± 0
Day 423.7 ± 1.9111.0 ± 2.950.38 ± 5.770 ± 0
Statistical analysis
  • Ketamine Followed by NRX-101 vs Ketamine Followed by Lurasidone · Mixed Models Analysis · p = .03 (BDM LS difference overall)BDM LS difference overall

Adverse events

Collected over Study Duration (6 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketamine Followed by NRX-1010/12 (0%)0/12 (0%)8/12 (66.7%)
Ketamine Followed by Lurasidone0/5 (0%)0/5 (0%)3/5 (60%)
Saline Followed by NRX-1010/4 (0%)0/4 (0%)4/4 (100%)
Saline Followed by Lurasidone0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 45
Most frequent other events
EventKetamine Followed by NRX-101Ketamine Followed by LurasidoneSaline Followed by NRX-101Saline Followed by Lurasidone
woundInjury, poisoning and procedural complications0/120/50/41/1
suicidal ideationPsychiatric disorders0/121/50/41/1
tinnitusEar and labyrinth disorders0/123/50/40/1
DizzinessNervous system disorders0/122/50/40/1
hypoasthesiaNervous system disorders0/122/50/40/1
palpitationsCardiac disorders0/120/51/40/1
tinnitusEar and labyrinth disorders0/120/51/40/1
vision blurredEye disorders2/121/51/40/1
dyspepsiaGastrointestinal disorders0/120/51/40/1
gastroesophageal reflux diseaseGastrointestinal disorders0/120/51/40/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ketamine Followed by NRX-101Ketamine Followed by LurasidoneSaline Followed by NRX-101Saline Followed by LurasidoneTotal
Mean33.9 ± 10.549 ± 8.941 ± 8.954 ± 039.5 ± 11.43
Sex: Female, Male
Sex: Female, Male(Participants)Ketamine Followed by NRX-101Ketamine Followed by LurasidoneSaline Followed by NRX-101Saline Followed by LurasidoneTotal
Female942116
Male31206
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ketamine Followed by NRX-101Ketamine Followed by LurasidoneSaline Followed by NRX-101Saline Followed by LurasidoneTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American10113
White1153019
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Ketamine Followed by NRX-101Ketamine Followed by LurasidoneSaline Followed by NRX-101Saline Followed by LurasidoneTotal
United States1254122
Columbia Suicide Severity Rating Scale (CSSRS)
Columbia Suicide Severity Rating Scale (CSSRS)(participants)Ketamine Followed by NRX-101Ketamine Followed by LurasidoneSaline Followed by NRX-101Saline Followed by LurasidoneTotal
CSSRS = 110001
CSSRS = 200000
CSSRS =300000
CSSRS =420002
CSSRS = 5954119
08

Study locations

4 sites
  • Research Site, Birmingham
    Birmingham, Alabama 35294, United States
  • Research Site, Fort Lauderdale
    Fort Lauderdale, Florida 33024, United States
  • Research Site, Charlotte
    Charlotte, North Carolina 28211, United States
  • Research Site, Houston
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Aug 2018, 7 months.

Results were first posted in May 2021, 2 years 8 months after primary completion.

Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 60. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2016
First posted
Nov 28, 2016
StartActual
Jan 15, 2018
Primary completionActual
Aug 31, 2018
CompletionActual
Nov 20, 2019
Results first posted
May 25, 2021
Last update
May 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02974010
Lead sponsor
NeuroRx, Inc.
Collaborators
Massachusetts General Hospital, Target Health Inc.
Responsible party
Sponsor
First posted
Nov 28, 2016
Start date
Jan 15, 2018
Primary completion
Aug 31, 2018
Completion
Nov 20, 2019
Results posted
May 25, 2021
Last update
May 25, 2021

Study contacts

Andrew Nierenberg, MD
principal investigator · Massachusetts General Hospital
Daniel C Javitt, MD
study director · NeuroRx, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desethyloxybutynin

Start the discussion